US 11,918,571 B2
Compounds and their methods of use
Kiran Reddy, Boston, MA (US); Gabriel Martinez Botella, Wayland, MA (US); Andrew Mark Griffin, L'lle Bizard (CA); and Brian Edward Marron, Ada, MI (US)
Assigned to Praxis Precision Medicines, Inc., Boston, MA (US)
Filed by Praxis Precision Medicines, Inc., Cambridge, MA (US)
Filed on Mar. 4, 2022, as Appl. No. 17/686,979.
Application 17/686,979 is a continuation of application No. 16/638,725, granted, now 11,278,535, previously published as PCT/US2018/000224, filed on Aug. 15, 2018.
Claims priority of provisional application 62/676,615, filed on May 25, 2018.
Claims priority of provisional application 62/545,555, filed on Aug. 15, 2017.
Prior Publication US 2022/0218681 A1, Jul. 14, 2022
Int. Cl. A61K 31/444 (2006.01); A61K 31/437 (2006.01); A61P 25/08 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 31/437 (2013.01); A61P 25/08 (2018.01)] 19 Claims
 
1. A method of treating a neurological disorder, wherein the neurological disorder is epilepsy or an epilepsy syndrome, wherein the method comprises administering to a subject in need thereof a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
each of X, Y, and Z is CR′;
A is phenyl or pyridyl, wherein the phenyl and the pyridyl are substituted with one or more R3;
R′ is hydrogen or C1-6 alkyl;
R1 is selected from the group consisting of hydrogen, deuterium and C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one or more R4;
each R3 is independently selected from the group consisting of C1-6 alkyl, C3-8 carbocyclyl, fluoro, chloro and —ORc, wherein the C1-6 alkyl and C3-8 carbocyclyl are optionally substituted with one or more R5;
each of R4 is independently selected from the group consisting of deuterium, fluoro, oxo, cyano, nitro and —ORc;
each of R5 is independently selected from the group consisting of C1-6 alkyl, deuterium, halogen, oxo, cyano, nitro, and —ORc, wherein the C1-6 alkyl is optionally substituted with one or more R7;
each Rc is independently selected from the group consisting of hydrogen, deuterium, C1-6 alkyl and C3-8 carbocyclyl wherein the C1-6 alkyl and C3-8 carbocyclyl are optionally substituted with one or more R6;
each R6 is independently selected from the group consisting of C1-6 alkyl, deuterium, C1-6 haloalkyl, C3-8 carbocyclyl, halogen, cyano, nitro, and —OH; and
and each R7 is independently selected from the group consisting of C1-6 alkyl, halogen and oxo.